(ARKG) ARK Genomic Revolution - Ratings and Ratios
Healthcare, Technology, Genomics, Equities, Growth
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 46.8% |
| Value at Risk 5%th | 74.2% |
| Relative Tail Risk | -3.59% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.59 |
| Alpha | 7.70 |
| CAGR/Max DD | -0.04 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.422 |
| Beta | 1.554 |
| Beta Downside | 1.296 |
| Drawdowns 3y | |
|---|---|
| Max DD | 51.96% |
| Mean DD | 26.77% |
| Median DD | 29.66% |
Description: ARKG ARK Genomic Revolution November 17, 2025
The ARK Genomic Revolution ETF (ARKG) is an actively-managed, non-diversified ETF that commits at least 80 % of its capital to domestic and foreign equities across sectors such as healthcare, information technology, materials, energy, and consumer discretionary, provided those companies are positioned to benefit from the genomics revolution.
Key quantitative points (as of the most recent public filings) include an expense ratio of 0.75 %, total assets under management of roughly $3 billion, and a top-10 holding concentration of about 30 %-indicating a relatively focused portfolio. The genomics sector is projected to grow at a compound annual growth rate of 12-15 % through 2030, driven by declining sequencing costs (now below $100 per genome) and expanding applications in personalized medicine, agriculture, and bio-manufacturing. Regulatory momentum, such as the FDA’s accelerated pathways for gene-editing therapies, serves as a macro-level catalyst for the underlying companies.
If you want a deeper, data-driven view of ARKG’s risk-return profile and how it fits into a broader genomics investment thesis, the ValueRay platform offers granular analytics that can help you evaluate the fund’s upside potential.
What is the price of ARKG shares?
Over the past week, the price has changed by +13.21%, over one month by -0.96%, over three months by +23.89% and over the past year by +24.24%.
Is ARKG a buy, sell or hold?
What are the forecasts/targets for the ARKG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 33.8 | 9.7% |
ARKG Fundamental Data Overview November 27, 2025
Beta = 2.38
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.09b USD (1.09b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 1.09b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 1.09b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 11.74% (E(1.09b)/V(1.09b) * Re(11.74%) + (debt-free company))
Discount Rate = 11.74% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for ARKG ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle